Literature DB >> 1295447

The cytoskeleton as a subcellular target of the antineoplastic drug lonidamine.

W Malorni1, S Meschini, P Matarrese, G Arancia.   

Abstract

Lonidamine (LND), a dichlorinated derivative of indazole-3-carboxylic acid, has proved to exert a powerful antiproliferative effect and to impair the energy metabolism of normal and neoplastic cells. A target effect of the drug on the cell membrane structure was hypothesized. Thus, in order to elucidate better the mechanism of action of LND, the drug effects on the cell surface as well as on main cytoskeletal elements, i.e. actin microfilaments, microtubules and intermediate filaments, were investigated. In particular, an immunocytochemical and ultrastructural study was performed using two different cell lines: epithelial squamous carcinoma (A431) and melanoma (M14) cells. Treatment with 0.8 mM LND for 8 hr induced a remarkable rearrangement of the F-actin molecules with the disappearance of the stress fibers. As far as microtubules are concerned, formation of perinuclear patches of tubulin were detected after LND treatment. Intermediate filaments appeared to be differently affected by LND in the two cell types. Such changes were detected as an early phenomenon and the extent of the effects observed was positively related to the cell surface alterations and to the loss of cell viability, suggesting that the cytoskeletal elements might represent an additional target in the mechanisms of cytotoxic action of LND.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1295447

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Anchoring junctions as drug targets: role in contraceptive development.

Authors:  Dolores D Mruk; Bruno Silvestrini; C Yan Cheng
Journal:  Pharmacol Rev       Date:  2008-05-15       Impact factor: 25.468

2.  Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.

Authors:  O Ben-Yoseph; J C Lyons; C W Song; B D Ross
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

3.  An in vivo study on adjudin and blood-testis barrier dynamics.

Authors:  Ilona A Kopera; Linlin Su; Barbara Bilinska; C Yan Cheng; Dolores D Mruk
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

4.  Adjudin disrupts spermatogenesis via the action of some unlikely partners: Eps8, Arp2/3 complex, drebrin E, PAR6 and 14-3-3.

Authors:  C Yan Cheng; Pearl Py Lie; Elissa Wp Wong; Dolores D Mruk; Bruno Silvestrini
Journal:  Spermatogenesis       Date:  2011-10-01

5.  The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.

Authors:  Shirin V Sundar; Julie Xia Zhou; Brenda S Magenheimer; Gail A Reif; Darren P Wallace; Gunda I Georg; Sudhakar R Jakkaraj; Joseph S Tash; Alan S L Yu; Xiaogang Li; James P Calvet
Journal:  Am J Physiol Renal Physiol       Date:  2022-08-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.